Treatment Effects in the Prostate Including Those Associated With Traditional and Emerging Therapies

被引:27
作者
Evans, Andrew J. [1 ]
Ryan, Paul [1 ]
Van derKwast, Theodorus [1 ]
机构
[1] Univ Hlth Network, Toronto Gen Hosp, Lab Med Program, Dept Pathol, Toronto, ON M5G 2C4, Canada
关键词
prostate; adenocarcinoma; hormonal therapy; radiation therapy; ablative therapies; INTENSITY-FOCUSED ULTRASOUND; NEOADJUVANT HORMONAL-THERAPY; CELL NEUROENDOCRINE CARCINOMA; TARGETED PHOTODYNAMIC THERAPY; EXTERNAL-BEAM RADIOTHERAPY; RADICAL PROSTATECTOMY; ANDROGEN BLOCKADE; INTRAEPITHELIAL NEOPLASIA; 5-ALPHA-REDUCTASE INHIBITORS; ACTIVE SURVEILLANCE;
D O I
10.1097/PAP.0b013e318220f5b1
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Classic treatment options for prostate cancer consist of radical prostatectomy, antiandrogen (or hormonal) therapy, and radiation therapy. Hormonal and radiation therapy, in particular, have well known, often profound effects on the histologic appearance of benign prostate tissue and prostatic carcinoma. The tissue changes induced by these treatments have been comprehensively described in several sources. Novel therapies ranging from focal ablative treatments to highly targeted molecular therapies are beginning to emerge and pathologists will play a central role in documenting the effects of these treatments on normal and malignant prostate tissue. It is therefore important that pathologists have access to basic treatment information and a solid working knowledge of the morphologic changes induced by these therapies. This will ensure accurate interpretation and reporting of posttreatment prostate specimens. This review is based on a presentation given by Dr A. Evans at the International Society of Urological Pathology Companion Society Meeting (Hot Topics in Urological Pathology) at The United States Canadian Academy of Pathology Meeting in Washington DC on March 20, 2010. This review will cover the histopathologic features seen in benign prostate tissue and prostatic carcinoma seen following: hormonal therapy, radiation therapy, ablative therapies such as vascular-targeted photodynamic therapy, interstitial laser thermotherapy, and high-intensity focussed ultrasound. An emphasis is placed on these specific modalities as they are currently in use as primary, salvage, or investigational therapy in the treatment of prostate cancer.
引用
收藏
页码:281 / 293
页数:13
相关论文
共 80 条
[71]   Vascular-targeted photodynamic therapy (padoporfin, WST09) for recurrent prostate cancer after failure of external beam radiotherapy: a study of escalating light doses [J].
Trachtenberg, John ;
Weersink, Robert A. ;
Davidson, Sean R. H. ;
Haider, Masoom A. ;
Bogaards, Arjen ;
Gertner, Mark R. ;
Evans, Andrew ;
Scherz, Avigdor ;
Savard, Joanne ;
Chin, Joseph L. ;
Wilson, Brian C. ;
Elhilali, Mostafa .
BJU INTERNATIONAL, 2008, 102 (05) :556-562
[72]   Effect of neoadjuvant endocrine therapy (combined androgen blockade) on normal prostate and prostatic carcinoma - A randomized study [J].
Vaillancourt, L ;
Tetu, B ;
Fradet, Y ;
Dupont, A ;
Gomez, J ;
Cusan, L ;
Suburu, ER ;
Diamond, P ;
Candas, B ;
Labrie, F .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1996, 20 (01) :86-93
[73]   Persistence of high-grade prostatic intra-epithelial neoplasia under combined androgen blockade therapy [J].
Van der Kwast, TH ;
Labrie, F ;
Têtu, B .
HUMAN PATHOLOGY, 1999, 30 (12) :1503-1507
[74]   Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume:: Three versus six months of endocrine therapy [J].
van der Kwast, TH ;
Têtu, B ;
Candas, B ;
Gomez, JL ;
Cusan, L ;
Labrie, F .
UROLOGY, 1999, 53 (03) :523-529
[75]   Histopathological changes associated with high intensity focused ultrasound (HIFU) treatment for localised adenocarcinoma of the prostate [J].
Van Leenders, GJLH ;
Beerlage, HP ;
Ruijter, ET ;
de la Rosette, JJMCH ;
van de Kaa, CA .
JOURNAL OF CLINICAL PATHOLOGY, 2000, 53 (05) :391-394
[76]   Small cell carcinoma of the prostate - A morphologic and immunohistochemical study of 95 cases [J].
Wang, Wenle ;
Epstein, Jonathan I. .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2008, 32 (01) :65-71
[77]   5-α-Reductase inhibitors for prostate cancer chemoprevention: an updated Cochrane systematic review [J].
Wilt, Timothy J. ;
MacDonald, Roderick ;
Hagerty, Karen ;
Schellhammer, Paul ;
Tacklind, James ;
Somerfield, Mark R. ;
Kramer, Barnett S. .
BJU INTERNATIONAL, 2010, 106 (10) :1444-1451
[78]   Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N-0 M(0) prostatic carcinoma [J].
Witjes, WPJ ;
Schulman, CC ;
Debruyne, FMJ .
UROLOGY, 1997, 49 (3A) :65-69
[79]   Long-term follow-up of 3-month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial [J].
Yee, David S. ;
Lowrance, William T. ;
Eastham, James A. ;
Maschino, Alexandra C. ;
Cronin, Angel M. ;
Rabbani, Farhang .
BJU INTERNATIONAL, 2010, 105 (02) :185-190
[80]   The feasibility and safety of high-intensity focused ultrasound as salvage therapy for recurrent prostate cancer following external beam radiotherapy. [J].
Ukimura, Osamu .
JOURNAL OF ENDOUROLOGY, 2009, 23 (02) :221-221